Jakavi 20mg Strip Of 14 Tablets

• Myelofibrosis includes primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis.
• Polycythemia vera patients who resist or cannot tolerate hydroxyurea, especially when myelofibrosis or polycythemia vera does not respond to it, require alternative treatments.
• Acute graft-versus-host disease, a complication of the transplant procedure that replaces diseased bone marrow with healthy bone marrow, has been previously treated unsuccessfully with steroid medications in adults and children aged 12 and older.

• Allergy to Ruxolitinib or any excipients of Jakavi tablet.
• Pregnancy and lactation.

• Infections:
• Urinary tract infections
• Herpes zoster
• CMV infections (cytomegalovirus)
• Sepsis
• Blood and Lymphatic System Disorders:
• Anaemia (low red blood cell count)
• Thrombocytopenia (low platelet count)
• Neutropenia (low neutrophil count)
• Bleeding (including various types such as bruising, gastrointestinal, intracranial, nosebleeds, post-procedural, and blood in urine)
• Bruising
• Metabolism and Nutrition Disorders:
• Hypercholesterolaemia (high cholesterol)
• Hypertriglyceridaemia (high triglycerides)
• Weight gain
• Nervous System Disorders:
• Dizziness
• Headache
• Gastrointestinal Disorders:
• Elevated lipase (an enzyme)
• Constipation
• Nausea
• Increased amylase (an enzyme)
• Hepatobiliary Disorders (liver & bile ducts):
• Increased alanine aminotransferase (ALT)
• Increased aspartate aminotransferase (AST)
• Vascular Disorders:
• Hypertension (high blood pressure)
• Musculoskeletal and Connective Tissue Disorders:
• Increased blood creatine phosphokinase (CPK)
• Renal and Urinary Disorders:
• Increased blood creatinine

Other General Warnings

• You have a lower platelet count.
• You develop signs or symptoms of an infection.
• You have an active serious infection.
• You have a history of tuberculosis or have been in close contact with someone who has tuberculosis.
• You have chronic Hepatitis B infection (as your doctor may need to monitor your HBV viral load).
• You notice early signs and symptoms of herpes zoster (shingles).
• You experience any new or worsening cognitive, neurological, or psychiatric symptoms or signs (as these could be suggestive of Progressive Multifocal Leukoencephalopathy (PML)).
• You have lipid abnormalities (high cholesterol or triglycerides).
• You are 65 years of age or older.
• You are a current or past long- time smoker.
• You have a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.
• You have cardiovascular risk factors.
• You have additional risk factors for venous thromboembolic events (VTE), such as a history of VTE, major surgery, immobilization, combined hormonal contraceptives or hormone replacement therapy, or an inherited coagulation disorder.
• You develop symptoms of thrombosis (such as leg swelling, pain, redness, or chest pain and shortness of breath).
• You have a history of extended treatment with hydroxyurea or prior non- melanoma skin cancer (NMSC) or pre- malignant skin lesions (as periodic skin examination is recommended).
• You have severe kidney impairment or are on haemodialysis (as your starting dose of Jakavi may need to be reduced).
• You have liver impairment.
• You experience a return of myelofibrosis (MF) symptoms after stopping or interrupting Jakavi.

Missed a Dose

Overdose

How Does It Work?

Interactions with other medicines